nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—ovarian cancer	0.593	1	CbGaD
Neostigmine—ABCB1—Topotecan—ovarian cancer	0.0839	0.354	CbGbCtD
Neostigmine—ABCB1—Vinorelbine—ovarian cancer	0.0591	0.249	CbGbCtD
Neostigmine—ABCB1—Paclitaxel—ovarian cancer	0.0415	0.175	CbGbCtD
Neostigmine—ABCB1—Docetaxel—ovarian cancer	0.03	0.127	CbGbCtD
Neostigmine—ABCB1—Doxorubicin—ovarian cancer	0.0224	0.0945	CbGbCtD
Neostigmine—BCHE—diaphragm—ovarian cancer	0.0162	0.413	CbGeAlD
Neostigmine—BCHE—myometrium—ovarian cancer	0.00196	0.0503	CbGeAlD
Neostigmine—ACHE—testis—ovarian cancer	0.00188	0.0481	CbGeAlD
Neostigmine—BCHE—uterine cervix—ovarian cancer	0.00153	0.0391	CbGeAlD
Neostigmine—BCHE—endometrium—ovarian cancer	0.00138	0.0354	CbGeAlD
Neostigmine—ACHE—lymph node—ovarian cancer	0.00136	0.0349	CbGeAlD
Neostigmine—BCHE—uterus—ovarian cancer	0.00127	0.0326	CbGeAlD
Neostigmine—BCHE—female reproductive system—ovarian cancer	0.00115	0.0293	CbGeAlD
Neostigmine—BCHE—bone marrow—ovarian cancer	0.00108	0.0277	CbGeAlD
Neostigmine—BCHE—vagina—ovarian cancer	0.00104	0.0265	CbGeAlD
Neostigmine—ABCB1—myometrium—ovarian cancer	0.000936	0.024	CbGeAlD
Neostigmine—BCHE—testis—ovarian cancer	0.000924	0.0236	CbGeAlD
Neostigmine—ABCB1—embryo—ovarian cancer	0.0009	0.023	CbGeAlD
Neostigmine—ABCB1—epithelium—ovarian cancer	0.000735	0.0188	CbGeAlD
Neostigmine—ABCB1—uterine cervix—ovarian cancer	0.000728	0.0186	CbGeAlD
Neostigmine—ABCB1—decidua—ovarian cancer	0.000694	0.0178	CbGeAlD
Neostigmine—BCHE—lymph node—ovarian cancer	0.00067	0.0171	CbGeAlD
Neostigmine—ABCB1—endometrium—ovarian cancer	0.000659	0.0169	CbGeAlD
Neostigmine—ABCB1—gonad—ovarian cancer	0.000611	0.0156	CbGeAlD
Neostigmine—ABCB1—uterus—ovarian cancer	0.000607	0.0155	CbGeAlD
Neostigmine—Dysarthria—Epirubicin—ovarian cancer	0.000595	0.00453	CcSEcCtD
Neostigmine—Skin disorder—Topotecan—ovarian cancer	0.000593	0.00451	CcSEcCtD
Neostigmine—Cardiovascular disorder—Doxorubicin—ovarian cancer	0.000592	0.00451	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.000592	0.0045	CcSEcCtD
Neostigmine—Hyperhidrosis—Topotecan—ovarian cancer	0.00059	0.00449	CcSEcCtD
Neostigmine—Tachycardia—Melphalan—ovarian cancer	0.000583	0.00444	CcSEcCtD
Neostigmine—Skin disorder—Melphalan—ovarian cancer	0.00058	0.00442	CcSEcCtD
Neostigmine—Atrioventricular block—Epirubicin—ovarian cancer	0.00058	0.00441	CcSEcCtD
Neostigmine—Pollakiuria—Paclitaxel—ovarian cancer	0.00057	0.00434	CcSEcCtD
Neostigmine—Lacrimation increased—Doxorubicin—ovarian cancer	0.000565	0.0043	CcSEcCtD
Neostigmine—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000561	0.00427	CcSEcCtD
Neostigmine—Hypotension—Melphalan—ovarian cancer	0.000558	0.00425	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000556	0.00423	CcSEcCtD
Neostigmine—Dysarthria—Doxorubicin—ovarian cancer	0.00055	0.00419	CcSEcCtD
Neostigmine—Salivary hypersecretion—Epirubicin—ovarian cancer	0.000546	0.00416	CcSEcCtD
Neostigmine—ABCB1—female reproductive system—ovarian cancer	0.000546	0.014	CbGeAlD
Neostigmine—Cramp muscle—Docetaxel—ovarian cancer	0.000545	0.00415	CcSEcCtD
Neostigmine—Urticaria—Chlorambucil—ovarian cancer	0.000545	0.00414	CcSEcCtD
Neostigmine—Arthralgia—Vinorelbine—ovarian cancer	0.000545	0.00414	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000544	0.00414	CcSEcCtD
Neostigmine—Dyspnoea—Topotecan—ovarian cancer	0.000544	0.00414	CcSEcCtD
Neostigmine—Abdominal pain—Chlorambucil—ovarian cancer	0.000542	0.00412	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000541	0.00412	CcSEcCtD
Neostigmine—Atrioventricular block—Doxorubicin—ovarian cancer	0.000537	0.00408	CcSEcCtD
Neostigmine—Dyspnoea—Melphalan—ovarian cancer	0.000533	0.00405	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000527	0.00401	CcSEcCtD
Neostigmine—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000522	0.00397	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000516	0.00393	CcSEcCtD
Neostigmine—ABCB1—bone marrow—ovarian cancer	0.000515	0.0132	CbGeAlD
Neostigmine—Bronchospasm—Docetaxel—ovarian cancer	0.000515	0.00392	CcSEcCtD
Neostigmine—Coma—Epirubicin—ovarian cancer	0.000514	0.00391	CcSEcCtD
Neostigmine—Nervous system disorder—Vinorelbine—ovarian cancer	0.000512	0.0039	CcSEcCtD
Neostigmine—Tachycardia—Vinorelbine—ovarian cancer	0.000509	0.00388	CcSEcCtD
Neostigmine—Skin disorder—Vinorelbine—ovarian cancer	0.000507	0.00386	CcSEcCtD
Neostigmine—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.000506	0.00385	CcSEcCtD
Neostigmine—Hypersensitivity—Chlorambucil—ovarian cancer	0.000505	0.00384	CcSEcCtD
Neostigmine—Bradycardia—Paclitaxel—ovarian cancer	0.000503	0.00383	CcSEcCtD
Neostigmine—Gastrointestinal pain—Topotecan—ovarian cancer	0.000499	0.0038	CcSEcCtD
Neostigmine—ABCB1—female gonad—ovarian cancer	0.000497	0.0127	CbGeAlD
Neostigmine—ABCB1—vagina—ovarian cancer	0.000494	0.0126	CbGeAlD
Neostigmine—Asthenia—Chlorambucil—ovarian cancer	0.000492	0.00374	CcSEcCtD
Neostigmine—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000488	0.00371	CcSEcCtD
Neostigmine—Hypotension—Vinorelbine—ovarian cancer	0.000488	0.00371	CcSEcCtD
Neostigmine—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000486	0.0037	CcSEcCtD
Neostigmine—Pruritus—Chlorambucil—ovarian cancer	0.000485	0.00369	CcSEcCtD
Neostigmine—Urticaria—Topotecan—ovarian cancer	0.000485	0.00369	CcSEcCtD
Neostigmine—Urethral disorder—Paclitaxel—ovarian cancer	0.000484	0.00369	CcSEcCtD
Neostigmine—Abdominal pain—Topotecan—ovarian cancer	0.000482	0.00367	CcSEcCtD
Neostigmine—Coma—Doxorubicin—ovarian cancer	0.000476	0.00362	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000476	0.00362	CcSEcCtD
Neostigmine—Urticaria—Melphalan—ovarian cancer	0.000475	0.00361	CcSEcCtD
Neostigmine—Diarrhoea—Chlorambucil—ovarian cancer	0.000469	0.00357	CcSEcCtD
Neostigmine—Dyspnoea—Vinorelbine—ovarian cancer	0.000465	0.00354	CcSEcCtD
Neostigmine—Flushing—Paclitaxel—ovarian cancer	0.000459	0.00349	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000451	0.00343	CcSEcCtD
Neostigmine—Hypersensitivity—Topotecan—ovarian cancer	0.00045	0.00342	CcSEcCtD
Neostigmine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000445	0.00339	CcSEcCtD
Neostigmine—Arrhythmia—Paclitaxel—ovarian cancer	0.000441	0.00336	CcSEcCtD
Neostigmine—ABCB1—testis—ovarian cancer	0.00044	0.0113	CbGeAlD
Neostigmine—Hypersensitivity—Melphalan—ovarian cancer	0.00044	0.00335	CcSEcCtD
Neostigmine—Asthenia—Topotecan—ovarian cancer	0.000438	0.00333	CcSEcCtD
Neostigmine—Vomiting—Chlorambucil—ovarian cancer	0.000436	0.00332	CcSEcCtD
Neostigmine—Mental disorder—Paclitaxel—ovarian cancer	0.000433	0.0033	CcSEcCtD
Neostigmine—Pruritus—Topotecan—ovarian cancer	0.000432	0.00329	CcSEcCtD
Neostigmine—Asthenia—Melphalan—ovarian cancer	0.000429	0.00326	CcSEcCtD
Neostigmine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000427	0.00325	CcSEcCtD
Neostigmine—Flatulence—Paclitaxel—ovarian cancer	0.000424	0.00323	CcSEcCtD
Neostigmine—Pruritus—Melphalan—ovarian cancer	0.000423	0.00322	CcSEcCtD
Neostigmine—Diarrhoea—Topotecan—ovarian cancer	0.000418	0.00318	CcSEcCtD
Neostigmine—Urticaria—Vinorelbine—ovarian cancer	0.000415	0.00316	CcSEcCtD
Neostigmine—Urinary tract disorder—Docetaxel—ovarian cancer	0.000414	0.00315	CcSEcCtD
Neostigmine—Muscle spasms—Paclitaxel—ovarian cancer	0.000414	0.00315	CcSEcCtD
Neostigmine—Abdominal pain—Vinorelbine—ovarian cancer	0.000413	0.00314	CcSEcCtD
Neostigmine—Connective tissue disorder—Docetaxel—ovarian cancer	0.000412	0.00313	CcSEcCtD
Neostigmine—Urethral disorder—Docetaxel—ovarian cancer	0.000411	0.00313	CcSEcCtD
Neostigmine—Diarrhoea—Melphalan—ovarian cancer	0.000409	0.00311	CcSEcCtD
Neostigmine—Osteoarthritis—Epirubicin—ovarian cancer	0.000408	0.00311	CcSEcCtD
Neostigmine—Nausea—Chlorambucil—ovarian cancer	0.000407	0.0031	CcSEcCtD
Neostigmine—Dizziness—Topotecan—ovarian cancer	0.000404	0.00307	CcSEcCtD
Neostigmine—Agitation—Paclitaxel—ovarian cancer	0.000395	0.00301	CcSEcCtD
Neostigmine—Flushing—Docetaxel—ovarian cancer	0.000389	0.00296	CcSEcCtD
Neostigmine—Cardiac arrest—Epirubicin—ovarian cancer	0.000388	0.00296	CcSEcCtD
Neostigmine—Vomiting—Topotecan—ovarian cancer	0.000388	0.00295	CcSEcCtD
Neostigmine—Syncope—Paclitaxel—ovarian cancer	0.000386	0.00294	CcSEcCtD
Neostigmine—Rash—Topotecan—ovarian cancer	0.000385	0.00293	CcSEcCtD
Neostigmine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000385	0.00293	CcSEcCtD
Neostigmine—Dermatitis—Topotecan—ovarian cancer	0.000384	0.00293	CcSEcCtD
Neostigmine—Headache—Topotecan—ovarian cancer	0.000382	0.00291	CcSEcCtD
Neostigmine—Vomiting—Melphalan—ovarian cancer	0.00038	0.00289	CcSEcCtD
Neostigmine—Loss of consciousness—Paclitaxel—ovarian cancer	0.000378	0.00288	CcSEcCtD
Neostigmine—Osteoarthritis—Doxorubicin—ovarian cancer	0.000378	0.00288	CcSEcCtD
Neostigmine—Mediastinal disorder—Docetaxel—ovarian cancer	0.000378	0.00287	CcSEcCtD
Neostigmine—Rash—Melphalan—ovarian cancer	0.000377	0.00287	CcSEcCtD
Neostigmine—Dermatitis—Melphalan—ovarian cancer	0.000376	0.00286	CcSEcCtD
Neostigmine—Asthenia—Vinorelbine—ovarian cancer	0.000375	0.00285	CcSEcCtD
Neostigmine—Arrhythmia—Docetaxel—ovarian cancer	0.000374	0.00285	CcSEcCtD
Neostigmine—Convulsion—Paclitaxel—ovarian cancer	0.000373	0.00284	CcSEcCtD
Neostigmine—Pruritus—Vinorelbine—ovarian cancer	0.000369	0.00281	CcSEcCtD
Neostigmine—Mental disorder—Docetaxel—ovarian cancer	0.000367	0.00279	CcSEcCtD
Neostigmine—Arthralgia—Paclitaxel—ovarian cancer	0.000366	0.00279	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000364	0.00277	CcSEcCtD
Neostigmine—Nausea—Topotecan—ovarian cancer	0.000362	0.00276	CcSEcCtD
Neostigmine—Cardiac arrest—Doxorubicin—ovarian cancer	0.000359	0.00273	CcSEcCtD
Neostigmine—Dry mouth—Paclitaxel—ovarian cancer	0.000358	0.00273	CcSEcCtD
Neostigmine—Diarrhoea—Vinorelbine—ovarian cancer	0.000357	0.00272	CcSEcCtD
Neostigmine—Nausea—Melphalan—ovarian cancer	0.000355	0.0027	CcSEcCtD
Neostigmine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000351	0.00267	CcSEcCtD
Neostigmine—Muscle spasms—Docetaxel—ovarian cancer	0.000351	0.00267	CcSEcCtD
Neostigmine—Shock—Paclitaxel—ovarian cancer	0.000345	0.00263	CcSEcCtD
Neostigmine—Dizziness—Vinorelbine—ovarian cancer	0.000345	0.00263	CcSEcCtD
Neostigmine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000344	0.00262	CcSEcCtD
Neostigmine—Tachycardia—Paclitaxel—ovarian cancer	0.000343	0.00261	CcSEcCtD
Neostigmine—Skin disorder—Paclitaxel—ovarian cancer	0.000341	0.0026	CcSEcCtD
Neostigmine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000339	0.00258	CcSEcCtD
Neostigmine—Vomiting—Vinorelbine—ovarian cancer	0.000332	0.00253	CcSEcCtD
Neostigmine—Rash—Vinorelbine—ovarian cancer	0.000329	0.0025	CcSEcCtD
Neostigmine—Dermatitis—Vinorelbine—ovarian cancer	0.000329	0.0025	CcSEcCtD
Neostigmine—Hypotension—Paclitaxel—ovarian cancer	0.000328	0.0025	CcSEcCtD
Neostigmine—Headache—Vinorelbine—ovarian cancer	0.000327	0.00249	CcSEcCtD
Neostigmine—Syncope—Docetaxel—ovarian cancer	0.000327	0.00249	CcSEcCtD
Neostigmine—Pollakiuria—Epirubicin—ovarian cancer	0.000326	0.00248	CcSEcCtD
Neostigmine—Loss of consciousness—Docetaxel—ovarian cancer	0.00032	0.00244	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00032	0.00243	CcSEcCtD
Neostigmine—ABCB1—lymph node—ovarian cancer	0.000319	0.00817	CbGeAlD
Neostigmine—Insomnia—Paclitaxel—ovarian cancer	0.000318	0.00242	CcSEcCtD
Neostigmine—Convulsion—Docetaxel—ovarian cancer	0.000316	0.0024	CcSEcCtD
Neostigmine—Drowsiness—Epirubicin—ovarian cancer	0.000315	0.0024	CcSEcCtD
Neostigmine—Dyspnoea—Paclitaxel—ovarian cancer	0.000313	0.00238	CcSEcCtD
Neostigmine—Somnolence—Paclitaxel—ovarian cancer	0.000312	0.00238	CcSEcCtD
Neostigmine—Arthralgia—Docetaxel—ovarian cancer	0.00031	0.00236	CcSEcCtD
Neostigmine—Nausea—Vinorelbine—ovarian cancer	0.00031	0.00236	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000308	0.00235	CcSEcCtD
Neostigmine—Dry mouth—Docetaxel—ovarian cancer	0.000304	0.00231	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000303	0.00231	CcSEcCtD
Neostigmine—Pollakiuria—Doxorubicin—ovarian cancer	0.000302	0.0023	CcSEcCtD
Neostigmine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000298	0.00227	CcSEcCtD
Neostigmine—Shock—Docetaxel—ovarian cancer	0.000293	0.00223	CcSEcCtD
Neostigmine—Nervous system disorder—Docetaxel—ovarian cancer	0.000292	0.00222	CcSEcCtD
Neostigmine—Drowsiness—Doxorubicin—ovarian cancer	0.000291	0.00222	CcSEcCtD
Neostigmine—Tachycardia—Docetaxel—ovarian cancer	0.00029	0.00221	CcSEcCtD
Neostigmine—Skin disorder—Docetaxel—ovarian cancer	0.000289	0.0022	CcSEcCtD
Neostigmine—Bradycardia—Epirubicin—ovarian cancer	0.000288	0.00219	CcSEcCtD
Neostigmine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000287	0.00219	CcSEcCtD
Neostigmine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000279	0.00212	CcSEcCtD
Neostigmine—Urticaria—Paclitaxel—ovarian cancer	0.000279	0.00212	CcSEcCtD
Neostigmine—Hypotension—Docetaxel—ovarian cancer	0.000278	0.00212	CcSEcCtD
Neostigmine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000278	0.00211	CcSEcCtD
Neostigmine—Abdominal pain—Paclitaxel—ovarian cancer	0.000278	0.00211	CcSEcCtD
Neostigmine—Urethral disorder—Epirubicin—ovarian cancer	0.000277	0.00211	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000271	0.00206	CcSEcCtD
Neostigmine—Insomnia—Docetaxel—ovarian cancer	0.000269	0.00205	CcSEcCtD
Neostigmine—Bradycardia—Doxorubicin—ovarian cancer	0.000266	0.00203	CcSEcCtD
Neostigmine—Dyspnoea—Docetaxel—ovarian cancer	0.000265	0.00202	CcSEcCtD
Neostigmine—Somnolence—Docetaxel—ovarian cancer	0.000265	0.00201	CcSEcCtD
Neostigmine—Flushing—Epirubicin—ovarian cancer	0.000262	0.002	CcSEcCtD
Neostigmine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000259	0.00197	CcSEcCtD
Neostigmine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000258	0.00196	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000257	0.00196	CcSEcCtD
Neostigmine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000257	0.00196	CcSEcCtD
Neostigmine—Urethral disorder—Doxorubicin—ovarian cancer	0.000256	0.00195	CcSEcCtD
Neostigmine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000255	0.00194	CcSEcCtD
Neostigmine—Arrhythmia—Epirubicin—ovarian cancer	0.000252	0.00192	CcSEcCtD
Neostigmine—Asthenia—Paclitaxel—ovarian cancer	0.000252	0.00192	CcSEcCtD
Neostigmine—Pruritus—Paclitaxel—ovarian cancer	0.000248	0.00189	CcSEcCtD
Neostigmine—Mental disorder—Epirubicin—ovarian cancer	0.000248	0.00188	CcSEcCtD
Neostigmine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000243	0.00185	CcSEcCtD
Neostigmine—Flushing—Doxorubicin—ovarian cancer	0.000243	0.00185	CcSEcCtD
Neostigmine—Flatulence—Epirubicin—ovarian cancer	0.000242	0.00184	CcSEcCtD
Neostigmine—Diarrhoea—Paclitaxel—ovarian cancer	0.00024	0.00183	CcSEcCtD
Neostigmine—Muscle spasms—Epirubicin—ovarian cancer	0.000236	0.0018	CcSEcCtD
Neostigmine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000236	0.00179	CcSEcCtD
Neostigmine—Abdominal pain—Docetaxel—ovarian cancer	0.000235	0.00179	CcSEcCtD
Neostigmine—Arrhythmia—Doxorubicin—ovarian cancer	0.000234	0.00178	CcSEcCtD
Neostigmine—Dizziness—Paclitaxel—ovarian cancer	0.000232	0.00177	CcSEcCtD
Neostigmine—Mental disorder—Doxorubicin—ovarian cancer	0.000229	0.00174	CcSEcCtD
Neostigmine—Agitation—Epirubicin—ovarian cancer	0.000226	0.00172	CcSEcCtD
Neostigmine—Flatulence—Doxorubicin—ovarian cancer	0.000224	0.00171	CcSEcCtD
Neostigmine—Vomiting—Paclitaxel—ovarian cancer	0.000223	0.0017	CcSEcCtD
Neostigmine—Rash—Paclitaxel—ovarian cancer	0.000221	0.00168	CcSEcCtD
Neostigmine—Dermatitis—Paclitaxel—ovarian cancer	0.000221	0.00168	CcSEcCtD
Neostigmine—Syncope—Epirubicin—ovarian cancer	0.000221	0.00168	CcSEcCtD
Neostigmine—Headache—Paclitaxel—ovarian cancer	0.00022	0.00167	CcSEcCtD
Neostigmine—Hypersensitivity—Docetaxel—ovarian cancer	0.000219	0.00167	CcSEcCtD
Neostigmine—Muscle spasms—Doxorubicin—ovarian cancer	0.000219	0.00167	CcSEcCtD
Neostigmine—Loss of consciousness—Epirubicin—ovarian cancer	0.000216	0.00165	CcSEcCtD
Neostigmine—Asthenia—Docetaxel—ovarian cancer	0.000214	0.00163	CcSEcCtD
Neostigmine—Convulsion—Epirubicin—ovarian cancer	0.000213	0.00162	CcSEcCtD
Neostigmine—Pruritus—Docetaxel—ovarian cancer	0.000211	0.0016	CcSEcCtD
Neostigmine—Arthralgia—Epirubicin—ovarian cancer	0.000209	0.00159	CcSEcCtD
Neostigmine—Agitation—Doxorubicin—ovarian cancer	0.000209	0.00159	CcSEcCtD
Neostigmine—Nausea—Paclitaxel—ovarian cancer	0.000209	0.00159	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000208	0.00158	CcSEcCtD
Neostigmine—Dry mouth—Epirubicin—ovarian cancer	0.000205	0.00156	CcSEcCtD
Neostigmine—Syncope—Doxorubicin—ovarian cancer	0.000204	0.00155	CcSEcCtD
Neostigmine—Diarrhoea—Docetaxel—ovarian cancer	0.000204	0.00155	CcSEcCtD
Neostigmine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000201	0.00153	CcSEcCtD
Neostigmine—Loss of consciousness—Doxorubicin—ovarian cancer	0.0002	0.00152	CcSEcCtD
Neostigmine—Shock—Epirubicin—ovarian cancer	0.000197	0.0015	CcSEcCtD
Neostigmine—Convulsion—Doxorubicin—ovarian cancer	0.000197	0.0015	CcSEcCtD
Neostigmine—Nervous system disorder—Epirubicin—ovarian cancer	0.000197	0.0015	CcSEcCtD
Neostigmine—Dizziness—Docetaxel—ovarian cancer	0.000197	0.0015	CcSEcCtD
Neostigmine—Tachycardia—Epirubicin—ovarian cancer	0.000196	0.00149	CcSEcCtD
Neostigmine—Skin disorder—Epirubicin—ovarian cancer	0.000195	0.00148	CcSEcCtD
Neostigmine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000194	0.00148	CcSEcCtD
Neostigmine—Arthralgia—Doxorubicin—ovarian cancer	0.000194	0.00147	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000192	0.00146	CcSEcCtD
Neostigmine—Dry mouth—Doxorubicin—ovarian cancer	0.000189	0.00144	CcSEcCtD
Neostigmine—Vomiting—Docetaxel—ovarian cancer	0.000189	0.00144	CcSEcCtD
Neostigmine—Rash—Docetaxel—ovarian cancer	0.000188	0.00143	CcSEcCtD
Neostigmine—Hypotension—Epirubicin—ovarian cancer	0.000188	0.00143	CcSEcCtD
Neostigmine—Dermatitis—Docetaxel—ovarian cancer	0.000187	0.00143	CcSEcCtD
Neostigmine—Headache—Docetaxel—ovarian cancer	0.000186	0.00142	CcSEcCtD
Neostigmine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000186	0.00141	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000183	0.00139	CcSEcCtD
Neostigmine—Shock—Doxorubicin—ovarian cancer	0.000183	0.00139	CcSEcCtD
Neostigmine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000182	0.00139	CcSEcCtD
Neostigmine—Insomnia—Epirubicin—ovarian cancer	0.000182	0.00138	CcSEcCtD
Neostigmine—Tachycardia—Doxorubicin—ovarian cancer	0.000181	0.00138	CcSEcCtD
Neostigmine—Skin disorder—Doxorubicin—ovarian cancer	0.00018	0.00137	CcSEcCtD
Neostigmine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00018	0.00137	CcSEcCtD
Neostigmine—Dyspnoea—Epirubicin—ovarian cancer	0.000179	0.00136	CcSEcCtD
Neostigmine—Somnolence—Epirubicin—ovarian cancer	0.000178	0.00136	CcSEcCtD
Neostigmine—Nausea—Docetaxel—ovarian cancer	0.000177	0.00135	CcSEcCtD
Neostigmine—Hypotension—Doxorubicin—ovarian cancer	0.000174	0.00132	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000173	0.00132	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000169	0.00129	CcSEcCtD
Neostigmine—Insomnia—Doxorubicin—ovarian cancer	0.000168	0.00128	CcSEcCtD
Neostigmine—Dyspnoea—Doxorubicin—ovarian cancer	0.000166	0.00126	CcSEcCtD
Neostigmine—Somnolence—Doxorubicin—ovarian cancer	0.000165	0.00126	CcSEcCtD
Neostigmine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000164	0.00125	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00016	0.00122	CcSEcCtD
Neostigmine—Urticaria—Epirubicin—ovarian cancer	0.000159	0.00121	CcSEcCtD
Neostigmine—Abdominal pain—Epirubicin—ovarian cancer	0.000159	0.00121	CcSEcCtD
Neostigmine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000152	0.00116	CcSEcCtD
Neostigmine—Hypersensitivity—Epirubicin—ovarian cancer	0.000148	0.00113	CcSEcCtD
Neostigmine—Urticaria—Doxorubicin—ovarian cancer	0.000148	0.00112	CcSEcCtD
Neostigmine—Abdominal pain—Doxorubicin—ovarian cancer	0.000147	0.00112	CcSEcCtD
Neostigmine—Asthenia—Epirubicin—ovarian cancer	0.000144	0.0011	CcSEcCtD
Neostigmine—Pruritus—Epirubicin—ovarian cancer	0.000142	0.00108	CcSEcCtD
Neostigmine—Diarrhoea—Epirubicin—ovarian cancer	0.000137	0.00105	CcSEcCtD
Neostigmine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000137	0.00104	CcSEcCtD
Neostigmine—Asthenia—Doxorubicin—ovarian cancer	0.000133	0.00101	CcSEcCtD
Neostigmine—Dizziness—Epirubicin—ovarian cancer	0.000133	0.00101	CcSEcCtD
Neostigmine—Pruritus—Doxorubicin—ovarian cancer	0.000131	0.001	CcSEcCtD
Neostigmine—Vomiting—Epirubicin—ovarian cancer	0.000128	0.000971	CcSEcCtD
Neostigmine—Diarrhoea—Doxorubicin—ovarian cancer	0.000127	0.000967	CcSEcCtD
Neostigmine—Rash—Epirubicin—ovarian cancer	0.000127	0.000963	CcSEcCtD
Neostigmine—Dermatitis—Epirubicin—ovarian cancer	0.000126	0.000962	CcSEcCtD
Neostigmine—Headache—Epirubicin—ovarian cancer	0.000126	0.000957	CcSEcCtD
Neostigmine—Dizziness—Doxorubicin—ovarian cancer	0.000123	0.000935	CcSEcCtD
Neostigmine—Nausea—Epirubicin—ovarian cancer	0.000119	0.000907	CcSEcCtD
Neostigmine—Vomiting—Doxorubicin—ovarian cancer	0.000118	0.000899	CcSEcCtD
Neostigmine—Rash—Doxorubicin—ovarian cancer	0.000117	0.000891	CcSEcCtD
Neostigmine—Dermatitis—Doxorubicin—ovarian cancer	0.000117	0.00089	CcSEcCtD
Neostigmine—Headache—Doxorubicin—ovarian cancer	0.000116	0.000886	CcSEcCtD
Neostigmine—Nausea—Doxorubicin—ovarian cancer	0.00011	0.00084	CcSEcCtD
